This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?
by Zacks Equity Research
McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
BSXPositive Net Change ISRGPositive Net Change MCKPositive Net Change HAEPositive Net Change
medical medical-devices
Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet
by Zacks Equity Research
Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.
UHSNegative Net Change ISRGPositive Net Change HAEPositive Net Change MASINegative Net Change
medical medical-devices
Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?
by Moumi Mondal
Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.
ABTPositive Net Change HOLXPositive Net Change QGENNegative Net Change
earnings-preview medical medical-devices
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
TMONegative Net Change HCAPositive Net Change TNDMPositive Net Change HIMSNegative Net Change
earnings medical
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
RHHBYNegative Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ironwood Pharmaceuticals (IRWD) stock based on the movements in the options market lately.
IRWDPositive Net Change
medical
Small Caps Climb on Interest Rate Cut Expectations: 5 Picks
by Nalak Das
We have narrowed our search to five small-cap stocks. These stocks are: AXL, NVRI, GRPN, BJRI, WGS.
BJRIPositive Net Change AXLNegative Net Change GRPNNegative Net Change WGSNegative Net Change NVRIPositive Net Change
auto-tires-trucks business-services internet-content medical restaurants
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
AMSCPositive Net Change LINCPositive Net Change CORTPositive Net Change ADMAPositive Net Change BTMDNegative Net Change
biotechnology consumer-discretionary medical tech-stocks
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
HUMNegative Net Change HALONegative Net Change SEMNegative Net Change ENOVNegative Net Change
medical
Catalent (CTLT) Expands Its Facility Capabilities in Germany
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
SYKPositive Net Change GMEDPositive Net Change CTLTNegative Net Change ELVNegative Net Change
medical medical-devices
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
by Zacks Equity Research
BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
BDXNegative Net Change DGXNegative Net Change UHSNegative Net Change DXCMPositive Net Change
medical medical-devices
Stryker (SYK) Completes Artelon's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.
UHSNegative Net Change SYKPositive Net Change HOLXPositive Net Change ELVNegative Net Change
medical medical-devices
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
by Zacks Equity Research
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
UHSNegative Net Change SYKPositive Net Change DVAPositive Net Change ELVNegative Net Change
medical medical-devices
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
BSXPositive Net Change GKOSPositive Net Change TNDMPositive Net Change EYENegative Net Change
earnings medical
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
BIIBPositive Net Change CGENNegative Net Change ARQTNegative Net Change LXEOPositive Net Change
medical
Retail Sales Came in Better Than Expected
by Zacks Equity Research
Retail Sales Came in Better Than Expected
AMZNNegative Net Change BACNegative Net Change MSNegative Net Change UNHPositive Net Change
finance medical tech-stocks
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTNegative Net Change ACADNegative Net Change AXSMPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNANegative Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
Stock Market News for Jul 16, 2024
by Zacks Equity Research
U.S stocks closed higher on Monday, building on Friday???s rally, as investors increased their bets on the chances of Donald Trump winning the U.S. presidential election in November following a failed assassination attempt on the Republican nominee over the weekend.
BACNegative Net Change JNJNegative Net Change NFLXNegative Net Change AXPNegative Net Change MARAPositive Net Change COINPositive Net Change
bitcoin blockchain consumer-discretionary cryptocurrency finance medical
Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop
by Zacks Equity Research
Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.
HAEPositive Net Change HIMSNegative Net Change AZTANegative Net Change HYPRNegative Net Change
medical
Integra's (IART) New Site to Produce Recalled Tissue Products
by Zacks Equity Research
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
IARTPositive Net Change HAEPositive Net Change GMEDPositive Net Change HIMSNegative Net Change
medical medical-devices
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
by Zacks Equity Research
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
HAEPositive Net Change CHEPositive Net Change GMEDPositive Net Change HIMSNegative Net Change
medical medical-devices
How to Play Intuitive Surgical (ISRG) Ahead of Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
ISRGPositive Net Change TMONegative Net Change DXCMPositive Net Change
medical medical-devices
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
CORTPositive Net Change NTLANegative Net Change TRDAPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals